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Abstract
The emergence of antibiotic resistance over the past several decades has given urgency to
new antibacterial strategies that apply less selective pressure. A new class of anti-virulence
compounds were developed that are active against methicillin-resistant Staphylococcus
aureus (MRSA), by inhibiting bacterial virulence without hindering their growth to reduce the
selective pressure for resistance development. One of the compounds CCG-211790 has
demonstrated potent anti-biofilm activity against MRSA. This new class of anti-virulence
compounds inhibited the gene expression of virulence factors involved in biofilm formation
and disrupted the biofilm structures. In this study, the physicochemical properties of CCG-
211790, including morphology, solubility in pure water or in water containing sodium dodecyl
sulfate, solubility in organic solvents, and stability with respect to pH were investigated for
the first time. Furthermore, a topical formulation was developed to enhance the therapeutic
potential of the compound. The formulation demonstrated acceptable properties for drug
release, viscosity, pH, cosmetic elegance and stability of over nine months.
Introduction
The rapid evolution and spread of antibiotic-resistant bacteria over the past several decades
have made antibiotic resistance a worldwide medical threat to humans [1, 2]. Conventional
antibiotics exert strong natural selection for drug-resistant bacteria by killing or inhibiting
drug-sensitive competitors [3]. The increasing occurrence of antibiotic-resistant strains calls
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for new antibacterial strategies that apply less selective pressure [4]. Antibiotic-resistance has
appeared in most common human pathogens. Among them, methicillin-resistance in Staphy-
lococcus aureus (MRSA) is approaching epidemic level [5, 6]. Staphylococcus aureus (S. aureus)
is one of the most common human pathogens, causing skin, soft tissue, respiratory, bone, joint
and endovascular infections, including life-threating bacteremia, endocarditis, sepsis and toxic
shock syndrome [7]. Novel antimicrobial agents that can replace or complement conventional
antibiotics could significantly enrich the therapeutic arsenal against antibiotic resistant bacte-
rial infections.
The novel anti-virulence approach of inhibiting pathogen virulence or disarming their
pathogenic weapons, while minimizing the selection pressure for resistance, is gaining recog-
nition as a viable alternative to traditional antibiotic treatment [8–11]. With the number of
anti-virulence studies growing exponentially in recent years, progress is being made toward
new approaches [12, 13]. However, most of the studies for anti-virulence molecules are still in
the preclinical stages. Only very recently, this anti-virulence paradigm started to bear fruit. For
example, Zinplava™ (Bezlotoxumab; Merck, Kenilworth, NJ, USA) was approved in 2016 as
one of the first anti-virulence drugs that can neutralize the toxin B of Clostridium difficile to
reduce recurrence and lower colitis and diarrhea, illustrating the tremendous potential of this
approach for solving the urgent antibiotic resistance problem. Other anti-virulence/anti-toxin
approaches have also advanced compounds into clinical development [14, 15].
A class of quinazolin-4-one derivatives were identified through high throughput screening
that inhibited the expression of a key Streptococcus pyogenes, or group A streptococcus (GAS),
virulence factor streptokinase, with the lead compound subsequently demonstrating in vivo
efficacy against GAS infection [16]. More studies demonstrated that analogs of the lead com-
pound also inhibited the biofilm formation of S. aureus [17]. These compounds block the pro-
duction of key virulence factors, especially those involved in biofilm formation. Biofilm is a
virulence mechanism that allows bacteria to colonize tissues and provide a physical barrier to
shield the bacteria from the body’s disease fighting white blood cells and antibodies. Biofilm
consists of complex structures of bacteria enveloped in extracellular polymeric matrix with
polysaccharides and water, together with excreted cellular products such as extracellular DNA
(eDNA), which stabilizes biofilm structures and contributes to antimicrobial resistance [18–
23]. Biofilm formation also contributes to antibiotic resistance by providing a physical barrier
to antibiotics [24, 25]. Infections caused by biofilm-associated pathogens are difficult to eradi-
cate because the biofilm structure, extracellular matrix, and inter-bacterial signaling of micro-
bial biofilm communities prevent antibiotic penetration, limit nutrition, promote bacterial
persistence and contribute to the antibiotic resistance of biofilm bacteria [18, 22, 23, 26–29].
Therefore, the production of biofilm-associated virulence factors makes bacteria harder to
treat and can transform infections from acute to chronic stage and lead to serious complica-
tions [27, 30]. S. aureus is one of the most frequent causes of biofilm-associated clinical infec-
tions [23, 28]. S. aureus is also a leading pathogen that may cause a variety of diseases ranging
from moderate to severe skin and soft tissue infections to very serious diseases such as endo-
carditis, osteomyelitis, septic shock, toxic shock syndrome, or necrotizing pneumonia [23, 28,
31]. Agents that decrease the protective biofilm will improve the effectiveness of treatment of
recalcitrant infections [21, 23, 30].
The current study reported a new anti-virulence compound CCG-211790 against S. aureus.
The physicochemical properties of CCG-211790, including morphology, solubility in pure
water or in water containing sodium dodecyl sulfate (SDS), solubility in organic solvents, and
stability with respect to pH were investigated for the first time. A topical formulation of this
novel class of anti-virulence compounds was developed and characterized. The new formula-
tion with anti-virulence compounds has potential to be developed into therapies to treat skin
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CCG-211790 was designed in the Vahlteich Medicinal Chemistry Core (VMCC) laboratory at
the University of Michigan. The compound was re-synthesized for the present studies in gram
scale by Active Biochem LTD (Kowloon, Hong Kong, China) by a proprietary route.
Described below is the lab scale synthesis developed by the VMCC. Ethanol was purchased
from Decon Laboratories Inc. (Detroit, MI, USA). SDS, glycerin, isopropyl alcohol, Dimethy-
lacetamide (DMA), dimethylformamide (DMF) and acetonitrile were purchased from Fisher
Scientific (Pittsburgh, PA, USA). Tween180 (polyoxyethylene-20-sorbitan monooleate) and
dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Pro-
pylene glycol was purchased from MP Biomedicals, LLC (Solon, OH, USA). Phosphate buff-
ered saline (10 mM) was purchased from Life Technologies Corp. (Carlsbad, CA, USA).
Deionized water was supplied from a reverse osmosis filtration system, Colligan Water (Rose-
mont, IL, USA) or prepared from an ELIX-3 water purification system (Millipore, Billerica,
MA, USA) for HPLC analysis. All the chemicals above were of analytical or high-performance
liquid chromatography (HPLC) grade. Liquid coconut oil, peanut oil, olive oil, sunflower oil,
sesame oil, canola oil, safflower oil and oleic acid were purchased from Piping Rock Health
Products, LLC (Ronkonkoma, NY, USA) and were used as received. Other materials in analyt-
ical grade were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Bacterial strains and culture conditions
Methicillin-resistant Staphylococcus aureus (MRSA) USA300 strain NRS384 (Strain USA300-
0114, NR-46070), was provided by the Network on Antimicrobial Resistance in Staphylococcus
aureus (NARSA) for distribution by BEI Resources, NIAID, NIH. The NRS384 strain was
grown in Todd-Hewitt broth containing 0.2% yeast extract (THY) (Difco, Detroit, MI, USA).
The medium for growth of static biofilms was THY with 0.5% glucose. All bacterial cultures
were incubated at 37˚C.
Synthesis of CCG-211790
CCG-211790 was synthesized as in Fig 1A using the following steps:
9-Methoxy-5,5-dimethyl-2-((2,2,2-trifluoroethyl)thio)-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (2). Intermediate 1 [32] (175 mg, 0.607 mmol) was combined with 1,1,1-tri-
fluoro-2-iodoethane (150 μL, 1.52 mmol) and sodium bicarbonate (1.5 equiv) in DMF (3 mL)
and warmed to 50˚C. The reaction was allowed to stir for 6 h at 50˚C, then was diluted with
water (10 mL) and extracted twice with ethyl acetate (2 × 10 mL). The organic extract was
washed with water (3 × mL) and brine (1 × 10 mL), then was dried over anhydrous MgSO4,
vacuum filtered, and concentrated in vacuo to give a yellow solid that was used without further
purification (208 mg, 93% yield). 1H NMR (400 MHz, Chloroform-d) δ 11.68 (s, 1H), 7.65 (d,
J = 2.7 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.94 (dd, J = 8.2, 2.7 Hz, 1H), 4.10 (q, J = 9.6 Hz, 2H),
3.85 (s, 3H), 2.74 (s, 2H), 1.40 (s, 6H).
9-Methoxy-3,5,5-trimethyl-2-((2,2,2-trifluoroethyl)thio)-5,6-dihydrobenzo[h]quinazo-
lin-4(3H)-one (CCG-211790). 2 (54 mg, 0.146 mmol) was dissolved in DMF (1 mL), to
which methyl iodide (23 mg, 0.16 mmol) and cesium carbonate (1.1 equiv) were added. The
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reaction was heated to 50˚C and allowed to stir for 16 hours, then diluted with H2O (10 mL)
and extracted 3 × 10 mL with EtOAc. The organic layer was washed with water (10 mL) and
brine (10 mL), then separated, dried over anhydrous MgSO4, vacuum filtered, and concen-
trated. Flash chromatography isolated only the N-alkylated isomer (32 mg, 57% yield). 1H
NMR (600 MHz, CDCl3): δ 7.64 (d, J = 2.8 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 6.95 (dd, J = 8.3,
2.9 Hz, 1H), 4.20 (q, J = 9.7 Hz, 2H), 3.87 (s, 3H), 3.57 (s, 3H), 2.75 (s, 2H), 1.39 (d, J = 3.5 Hz,
6H). 13C NMR (151 MHz, CDCl3): δ 161.55, 158.61, 155.64, 151.76, 132.75, 129.45, 124.80 (q,
J = 276.5 Hz), 122.22, 122.05, 116.88, 109.62, 55.19, 43.81, 33.81, 33.22 (q, J = 34.2 Hz), 30.30,
25.84. ESI+ MS m/z = 385.0 (M + H+) 407.0 (M + Na+). Reverse phase HPLC purity>95%.
Biofilm assay
The biofilm assay was performed using 96-well polystyrene flat-bottom microtiter plate as
described previously [17]. Overnight cultures of S. aureus were diluted 1:200 with fresh THY
medium containing 0.5% glucose. Aliquots of 200 μL bacteria culture was incubated in wells of
96-well microtiter plates with different concentration of CCG-211790 (0.39, 0.78, 1.56, 3.13,
6.25, 12.5, 25, 50 μM) or control DMSO in triplicate at 37˚C overnight. Non-adherent bacteria
were washed away by PBS three times. Biofilms attached to microtiter plates were stained by
crystal violet solution (Sigma-Aldrich, St. Louis, MO, USA) for 15 min. Excess stain was
removed by washing with PBS. The crystal violet attached to biofilm samples was dissolved
with ethanol. The absorbance at 595 nm was measured using Spectrostar Nano spectropho-
tometer (BMG Labtech, Ortenberg, Germany) as the value of biofilm formation. Percentage
inhibition of sample treated with CCG-211790 was calculated against the mean of samples
treated with DMSO. Experiments were repeated three times to obtain the mean and standard
deviation of biofilm formation under each treatment. IC50 (the half maximal inhibitory con-
centration) was estimated.
Fig 1. Synthesis and cytotoxicity of CCG-211790 A) Synthesis of CCG-211790 B) Mammalian cell viability in the
presence of CCG-211790 at different concentrations normalized to the value for DMSO treated samples which was
defined as 100%. The data is presented as mean ± standard deviation for a total of 4 samples (pooled from 2
independent experiments in duplicates).
https://doi.org/10.1371/journal.pone.0246408.g001
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Microsomal stability
Microsomal stability assay was performed as previously described [32]. CCG-211790 (100 mM
stock solution in DMSO) was diluted 1000-fold with phosphate-buffered saline (PBS) contain-
ing up to 10% MeOH as a co-solvent. Compound (100 μM) was added to 366 μL of 100 mM
phosphate buffer containing 3.3 mM MgCl2 and 10 μL of 20 mg/mL mouse liver microsomal
extract (XenoTech, Lenexa, KS, USA). Enzymatic oxidation was initiated by adding 15 μL of
16.7 mg/mL NADPH in 100 mM phosphate buffer containing 3.3 mM MgCl2. The reactions
were carried out at 37˚C for 60 min. Aliquots of the reaction mixture (30 μL) were sampled
and the reaction was stopped by adding 90 μL cold acetonitrile containing an internal standard
compound at each time point (0, 1, 3, 5, 10, 30, and 60 min). The quenched sample mixtures
were centrifuged at 16,000 g for 10 min. The supernatant was then analyzed via an LC–MS/MS
system equipped with a reverse-phase column.
Mammalian cell cytotoxicity assay
Cell cytotoxicity assay was performed by following previous protocols with minor revision
[17]. TZM-bL cells which is a HeLa cell derivative (a generous gift from Dr. Xiao Heng, Uni-
versity of Missouri) (100 μL, 5,000 cells per well) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum
for 24 h at 37˚C in 5% CO2 in duplicates. Supernatant was replaced with 100 μL fresh medium
with different concentrations of CCG-211790 to culture the cells for 24 h at 37˚C in 5% CO2.
DMSO was used as the vehicle control. Ten μL of Cell Counting Kit-8 (CCK-8) solution
(APExBIO, Houston, TX, USA) was added to each well of the plate. After 2 h, the plate was
read at 450 nm by using a BioTek spectrophotometer (BioTek, Winooski, VT, USA). One hun-
dred percent viability was set at the absorbance of the cells treated with only the vehicle
(DMSO). The assay was performed twice in duplicates to obtain the mean and standard devia-
tion of cell viability. The cell viability (survival rate) was calculated with the equation: Survival
rate (%) = [(As—Ab) / (Ac—Ab)] x 100, As = Absorbance of tested compound (Absorbance of
well containing cells, culture medium, CCK-8 and compound), Ab = Absorbance of blank
(Absorbance of well containing culture medium and CCK-8), Ac = Absorbance of control
(Absorbance of well containing cell, DMSO and CCK-8).
Scanning Electron Microscopy (SEM)
Morphology of CCG-211790 bulk powder was examined using a FEI Quanta 600 FEG Envi-
ronmental Scanning Electron Microscope (FEI Company, Hillsboro, OR, USA). CCG-211790
bulk powder was used as received. The sample was fixed on an aluminum SEM stage with a
conductive double-sided carbon tape and sputter-coated with 5 nm of platinum prior to mea-
surement in order to increase sample conductivity. SEM measurements were carried out at an
accelerating voltage of 5 kV and a work distance of 8–9 mm.
Ultraviolet-visible spectrophotometry (UV-Vis)
The concentration of CCG-211790 in organic solvents was carried out on a LabTech BlueStar
plus UV-Vis spectrophotometer (Hopkinton, MA, USA) using dimethylformamide (DMF) as
a reference solvent. UV-Vis absorption spectra were recorded in a wavelength range from
200–500 nm with samples placed in a quartz cuvette. CCG-211790 concentrations in organic
solvents were determined based on the absorption of CCG-211790 at characteristic wavelength
of 314 nm. Calibration curves were established giving a correlation coefficient more than
0.999.
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High-Performance Liquid Chromatography (HPLC)
The concentration of CCG-211790 in deionized water or aqueous solutions was determined
using an Agilent series 1100 HPLC system (Agilent Technologies, Santa Clara, CA, USA)
equipped with diode array detector. Sample separation was carried out with a Kinetex C18 col-
umn (75 mm × 3 mm, particle size 2.6 μm, Phenomenex Inc., Torrance, CA, USA). The mobile
phase of acetonitrile-water (50:50, v/v) was used for chromatographic separation. The flow rate
was set to 0.5 mL/min, column temperature to 35˚C. The absorption was measured at wave-
length 255 nm. The injection volume was 30 μL. The retention time of CCG-211790 was 4.9
min. The method detection limit was 0.02 mg/L. Calibration curves were established giving a
correlation coefficient >0.9900.
Solubility in water
To determine the solubility of CCG-211790 in water [33], an excess amount of CCG-211790
powder was added into water. After incubation for 20 h at room temperature on a shaking
platform, it still showed visible milky turbidity. The sample aliquots (0.5 mL each) were centri-
fuged at 20,000 ×g for 5 min with Amicon Ultra-0.5 Centrifugal Filter Units (MWCO 3000
Da, Millipore Corp., Billerica, MA, USA). Solutions passing through the filter were diluted
2-fold with acetonitrile and CCG-211790 concentration in water was determined by HPLC
analysis. The experiment was run in triplicate with mean values and standard deviations being
reported.
Solubility in water containing Sodium Dodecyl Sulfate (SDS)
The procedure to determine solubility in water with presence of SDS is based on the Paddle
Method as described in the U.S. Pharmacopeia <711> on the in vitro dissolution tests with
minor revision. To determine the saturation solubility in water containing SDS, CCG-211790
bulk powder was added in excess (around 5 mg of CCG-211790) to 10 mL of SDS solutions
with various concentrations (0.5, 1.0 or 2.0% w/v). After incubation for 24–48 h in a shaking
incubator at 37˚C and 200 rpm to reach saturation status, aliquot (2 mL) of the incubated sam-
ple was filtered through a 0.22 μm Millipore filter (Millipore Corp., Billerica, MA, USA). Solu-
tions passing through the filter were collected (0.5 mL) and were diluted 2-fold with
acetonitrile. CCG-211790 concentration in SDS solutions was determined by HPLC analysis.
Solubility in organic solvents
The solubility of CCG-211790 in organic solvents were also determined [33]. CCG-211790
bulk powder was added in excess to 0.1–1 mL of an organic solvent. After ultrasonication for
30 min and incubation for 24 h at room temperature on a shaking platform to reach the satura-
tion status, sample aliquots (0.5 mL) were centrifuged at 10,400 ×g for 10 min, and 10 μL of
supernatant was diluted 500–50,000-fold with dimethylformamide (DMF). The saturation sol-
ubility of CCG-211790 in various organic solvents was determined via ultraviolet-visible spec-
trophotometry (UV-Vis) with DMF as the reference solvent.
Effect of pH on CCG-211790 degradation
Effect of pH on CCG-211790 degradation was investigated at indicated pH (1–10) over a
period of three months [34, 35]. Briefly, pH 1, 2 or 10 were achieved by dissolving CCG-
211790 bulk powder in a mixture of acetonitrile and water (25:75, v/v) with the pH being
adjusted with hydrochloride acid solution (12 mole/L) or sodium hydroxide solution (15
mole/L). Similarly, pH 3–9 were achieved by dissolving CCG-211790 powder in a mixture of
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acetonitrile and PBS (25:75, v/v) with the pH also being adjusted with the hydrochloride acid
solution or the sodium hydroxide solution. All samples were incubated at 37˚C. CCG-211790
concentrations in the mixture solutions were determined via HPLC analysis at predetermined
time points (0, 2, 4 and 12 weeks).
Preparation of cream formulation of CCG-211790
The following protocol was used for preparing 100g CCG-211790 (0.3%, 1%, 3% w/v) cream:
Water (33.1%, 32.4%, 30.4% w/v), citric acid (0.07% w/v), and sodium citrate (0.23% w/v)
were stirred at room temperature until completely dissolved. Xanthan gum (0.2% w/v) was
gently added into the solution under vigorously stirring (400 rpm), then stirred at 500 rpm
until the gum completely dissolving to be used as aqueous phase (phase A). Isopropyl myristate
(IPM, 10.5% w/v), mineral oil (42.2% w/v), Stearyl alcohol (3.6% w/v), cetyl alcohol (3.6% w/v),
BRIJ1 58 (6.2% w/v) and CCG-211790 (0.3%, 1%, 3% w/v) were stirred into the oil mixture
(phase B). Phase A and phase B were maintained in water bath (70–80˚C) for 5–6 min under
stirring at 500 rpm. CCG-211790 was added into phase B after maintaining phase B in the
water bath for 3 min and stirred at 500 rpm for another 3 min. Phase B solution was added
into phase A and immediately homogenized with a high-speed homogenizer (T18, IKA) at
15,000 rpm for 3 min to prepare emulsion. The obtained emulsion was stirred and cooled
down to room temperature using a homogenizer (SciLogex OS40-S, SCILOGEX, LLC, Rocky
Hill, CT, USA) at 100 rpm for 10 min and then 50 rpm for another 10 min. The cream was
ready for use after cooling to room temperature.
Drug release profile (Franz Chamber Assay)
The Franz Chamber Protocol was used for evaluating drug release using published methods
[36, 37] as follows: 1) Prepare receiving medium (2% SDS in Ethanol/Water (40/60)), and
degas the medium by ultrasound bath; 2) Turn on the machine and adjust the temperature at
32˚C; 3) Saturate the membrane (Polycarbonate (0.4 μm)) in receiving medium for 30 min; 4)
Apply membrane on the dosage wafer, and apply spatula to spread out cream on the mem-
brane (200 mg for 0.3% and 1.0%, 100 mg for 3.0%); 5) Add medium into receptor and place
the wafer and membrane on the receptor without bubbles; 6) Use clamp to fix the donor and
receptor; 7) Seal the donor chamber using sealing film; 8) Set the stirring speed at 600 rpm,
and start the machine; 9) Stop stirring 30 seconds before sampling, take 300 μL medium at 0.5
h, 1 h, 2 h, 3 h, 4 h and 6 h, and refill with fresh medium.
Quality target product profile of the CCG-211790 cream
The oil phase solubilizes the active agent, CCG-211790, which is emulsified with water, surfac-
tants, and thickening agents to provide the desired viscosity and stability. The emulsion has
the acceptable properties for drug release (Franz Chamber Analysis), viscosity, pH, cosmetic
elegance (no smell, non-greasy, spreadability, quick drying, and non-irritating) and stability
with over nine months testing completed.
Statistic
Statistical analysis of the results was performed using a two-sided Student’s t-test. Dose
Response fitting function in Origin was used to calculate the IC50. The IC50 was calculated by
plotting the inhibition percentage (y) versus logarithm of dose (x), and fitting the data using
the equation y ¼ A1 þ
A2   A1
1þ10ðLogx0   xÞp
. IC50 was calculated as 10
logx0 . A1 stands for bottom
PLOS ONE Characterization and formulation development of novel anti-biofilm compound
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asymptote, A2 stands for top asymptote and p is the hill slope (Origin 7.0, OriginLab Corpora-
tion, Northampton, MA, USA).
Results
Generation of CCG-211790 as an inhibitor of Staphylococcus aureus
biofilm formation
CCG-211790 was designed and synthesized as part of a structure-relationship analysis (SAR)
in developing anti-virulence compounds against S. aureus biofilm formation (Fig 1A), follow-
ing the discovery of lead compounds CCG-203592 and CCG-205363 [17, 32]. In the larger
SAR program that was described previously [32], 87 analogs of the lead compounds were iden-
tified with> 20% inhibition of S. aureus biofilm at 100 or 50 μM [38]. CCG-211790 was
selected for further analysis of its therapeutic potential because of its potent S. aureus anti-bio-
film activity, and its relatively high stability to incubation with mouse liver microsomes.
The effect of CCG-211790 on biofilm formation was tested with S. aureus NRS384 strain,
which is widely used for studying MRSA infections. NRS384 was treated with different con-
centrations of CCG-211790, and the IC50 of the inhibition of biofilm formation was calculated.
CCG-211790 inhibited biofilm formation with IC50 = 1.28±0.45 μM, which is more potent
than the previous lead compounds CCG-203592 and CCG-205363 [17]. The half-life of CCG-
211790 in mouse liver microsomes (t1/2) is 19.6 min while CCG-203592 (t1/2 = 0.8 min) and
CCG-205363 (t1/2 = 0.6 min) have lower half-life [32].
Stability to mouse liver microsomes is one predictor of half-life in vivo in mice. CCG-
211790 was designed to be stable to oxidative metabolism of the S-substituent. A metabolic
identification study of an early lead analog, described in Yestrepsky et al. [32], indicated that
the S-substituent is a primary site of metabolism by CYP enzymes, therefore the terminus of
the S-ethyl group with fluorine atoms, which are known to be resistant to oxidative metabo-
lism, was blocked [39]. As a result, CCG-211790 demonstrated a metabolic stability superior
to all of the structurally-related compounds evaluated in that earlier work [32]. It also demon-
strated more broad-spectrum and potent anti-virulence activity against Streptococcus pyogenes
(manuscript in preparation). It was thus selected as a candidate for further characterization of
its potential to become a therapeutic agent.
Cytotoxicity of CCG-211790 to mammalian cells was also tested on TZM-bL cells which is
a HeLa cell derivative. The cytotoxicity of CCG-211790 at concentrations of 6.25, 12.5, 25, and
50 μM was measured by the colorimetric CCK8 viability assay and compared to cell viability
when treated with DMSO control (Fig 1B). At 50 μM, the CCG-211790 displayed cytotoxic
activity on TZM-bL cells and the cell survival rate was 56.1±5.3%, which is about 39-fold of the
anti-biofilm IC50 of the compound, indicating that CCG-211790 has a wide selectivity window.
Lower concentrations of CCG-211790 have little toxicity against human cells but have signifi-
cant anti-biofilm activity.
Morphology
The SEM images of CCG-211790 bulk powder, as seen in Fig 2, showed that CCG-211790 bulk
powder consisted of either medium rod-like particles with length in up to twenty micrometers
and diameter in a few micrometers, or large, thick particles with length over fifty micrometers
and diameter over twenty micrometers. A few of small plate-like particles with length up to
three micrometers also existed (Fig 2C), and their smooth planes and edges suggested that
those particles were well-developed CCG-211790 crystals with oriented growth.
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Solubility
The solubility of CCG-211790 in water was 0.038 ±0.01 μg/mL, determined by HPLC analysis.
CCG-211790 can be classified as practically insoluble compound (solubility less than 100 μg/
mL) according to the definition of US Pharmacopeia [33]. Poor aqueous solubility of drugs is
usually associated with pharmaceutical problems such as erratic absorption and poor bioavail-
ability leading to insufficient drug concentrations at the site of action for pharmacological
response [40, 41], and has become one of major challenges in pharmaceutical industries [42,
43].
In vitro dissolution testing is an important tool in pharmaceutics that can be used to predict
in vivo performance of certain products or for the purpose of quality control [44, 45]. Prior to
conducting a dissolution testing, the dissolution medium is usually selected based on the solu-
bility data and the dose range of the drug product in order to achieve sink condition, where
the volume of dissolution medium is at least three times the volume needed to form a saturated
solution of the drug substance being measured [44]. SDS, synonymously sodium lauryl sulfate
(SLS), is the most frequently used artificial surfactants in dissolution testing [46]. The presence
of SDS in dissolution medium is able to increase the solubility of water-insoluble drugs and
therefore, less quantity of dissolution medium is needed to meet sink conditions. Solubility of
CCG-211790 in SDS solution after incubation at 37˚C and 200 rpm for 24 or 48 h is shown in
Table 1. To conduct a dissolution testing in 0.5% SDS solution at a dose of 5 mg of CCG-
211790, a minimum of 500 mL of dissolution medium is required to meet sink condition.
Solubility of CCG-211790 in various organic solvents was investigated using UV-Vis analy-
sis, as seen in Table 2. Dimethylacetamide (DMA), dimethylformamide (DMF) and dimethyl
sulfoxide (DMSO) have the highest solvent power for CCG-211790, which are 278.5, 215.4 and
66.7 mg/mL respectively. DMSO is a polar aprotic solvent that has been widely used in phar-
maceutics and biological studies [47].
Higher solubility of DMSO for CCG-211790 over other solvents such as various edible oils
and Acetonitrile indicates DMSO would be a promising organic solvent for CCG-211790 in
preliminary studies. Edible oils listed in Table 2 are commonly used pharmaceutical excipients
[47]. CCG-211790 solubility in these edible oil ranges from 20–37.2 mg/mL, giving potential
for these edible oils to be used as vehicles for CCG-211790 in oral formulation development.
Fig 2. SEM images of CCG-211790 bulk powder after sputter-coating of 5 nm of platinum.
https://doi.org/10.1371/journal.pone.0246408.g002
Table 1. Solubility of CCG-211790 bulk powder in 0.5, 1.0 or 2.0% SDS solution after incubation in a shaking
incubator at 37˚C and 200 rpm for 24 or 48 h.
SDS concentration Solubility (μg/mL)
(w/v) 24 h 48 h Mean
0.5% 32.9 26.8 29.9 ± 4.3
1.0% 68.5 63.8 66.1 ± 3.3
2.0% 161.4 149.7 155.5± 8.3
https://doi.org/10.1371/journal.pone.0246408.t001
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Effect of pH on CCG-211790 stability
Solubility of CCG-211790 under various pH conditions in a mixture of acetonitrile/water (pH
1, 2 or 10) or acetonitrile/PBS (pH 3–9) when incubated at 37˚C over a period of twelve weeks
was shown in Table 3. While CCG-211790 degraded at pH 1, it maintained most chemical sta-
bility at pH 2–10, which includes most physiological conditions of between pH 5–7.
Formulation of CCG-211790 for topical application
Because many MRSA infections are skin or soft tissue, a topical delivery of an anti-virulence
agent would be therapeutically useful and would help test the proof of concept for controlling
infections with an anti-virulence agent. Using Quality by Design principles, a topical formula-
tion was developed composed of FDA approved “generally recognized as safe” (GRAS)
Table 2. CCG-211790 solubility in various organic solvents at room temperature.

















Table 3. Change of CCG-211790 concentration in the mixture solution of acetonitrile/water or acetonitrile/PBS
with pH from 1–10 when incubated at 37˚C over a period of twelve weeks.
pH CCG-211790 concentration (μg/mL)
0 week 2 weeks 4 weeks 12 weeks
1 11.1 9.4� 7.2�� 2.1��
2 11.6 11.9 11.2� 10.7�
3 11.9 11.9 11.4 11.7
4 10.9 11.4 11.6� 11.3
5 11.0 11.3� 11.5 11.2
6 11.1 11.4 11.0 10.1
7 11.8 11.2� 10.9� 11.5
8 11.2 11.2 11.1 11.6
9 11.0 11.3� 11.2 10.5
10 10.4 11.0� 10.5 10.7�
� Statistical significance compared with initial concentrations measured at 0 week when P<0.05.
�� Statistical significance compared with initial concentrations measured at 0 week when P<0.01.
https://doi.org/10.1371/journal.pone.0246408.t003
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excipients that are listed in the FDA’s Inactive Ingredient Database. In compliance with EP or
USP the excipients contribute to the desired profile of the cream. The details of the topical
compositions of CCG-211790 in the cream emulsion are listed in Table 4.
The components included: mineral oil and isopropyl myristate (IPM) as oil phase, PEG 20
cetyl ether as surfactant, stearyl alcohol as stiffening agent, cetyl alcohol for emulsifier/stiffen-
ing, xanthan gum for thickening, water as aqueous phase and citric acid and sodium citrate as
buffer. The oil phase solubilizes the active agent, CCG-211790, which is emulsified with water,
surfactants, and thickening agents.
The drug release testing and performance parameters of the above-mentioned cream for-
mulations were conducted using the standard Franz Chamber testing method for drug
release and penetration and performance analysis. Drug release profile (Franz Chamber
Assay) was carried out to measure drug release from this dosage form. For semisolid drug
products (such as a cream formulations), release properties can be evaluated by in vitro
release testing (IVRT). An in vitro release rate can reflect the combined effect of several phys-
ical and chemical parameters, such as solubility and particle size of the active pharmaceutical
ingredient (API or drug) and rheological properties of the dosage form [48, 49]. The Franz
diffusion cell can be used to assess drug release and skin permeability, leading to understand-
ing of the relationships between skin, drug and formulation [48, 49]. Such testing is highly
useful in the design and development of novel formulations, toxicity screening [50] and qual-
ity control of drug release profile if skin is used rather that artificial membranes [51–53]. The
method of Ng et al. [54] with synthetic membranes was used, which has been demonstrated
to correlate with human and pig skin for drug release profiling and penetration [55]. This
method also allows for reproducible results compared to those using skin samples that vary
from experiment to experiment. The drug release from topical formulation is different from
other drug delivery systems. FDA has issued a guidance [56], in which section VII. claimed
release was theoretically proportional to the square root of time (
p
t). Thus, the in vitro
release study was performed as per the guidance. Some other studies also use the same way to
characterize in vitro release [57, 58].
The drug release parameters are included in Table 5. The drug release curves are illustrated
in Fig 3. The concentration released over a 3h period for 0.3, 1% and 3%, was approximately
16 μg/mL (42 μM), 36 μg/mL (94 μM), and 77 μg/mL (200 μM), which is more than 30 times
above the antibiofilm IC50.
Table 4. Compositions of cream emulsions with different CCG-211790 drug loads.
Excipient Component%
0% Drug load 0.3% Drug load 1% Drug load 3% Drug load
Isopropyl myristate (IPM) 10.5 10.5 10.5 10.5
Mineral oil 42.2 42.2 42.2 42.2
BRIJ1 58 6.2 6.2 6.2 6.2
Stearyl alcohol 3.6 3.6 3.6 3.6
Cetyl alcohol 3.6 3.6 3.6 3.6
Xanthan gum 0.2 0.2 0.2 0.2
Water 33.4 33.1 32.4 30.4
Citric acid 0.07 0.07 0.07 0.07
Sodium citrate 0.23 0.23 0.23 0.23
CCG-211790 0 0.3 1 3
Total 100% 100% 100% 100%
https://doi.org/10.1371/journal.pone.0246408.t004
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Quality target product profile of the CCG-211790 cream
The quality target product profile was also tested and summarized in Table 6, whereas the sta-
bility data is included in Table 7.
Discussion
In the ongoing SAR effort to develop the novel anti-virulence class of compounds [16, 17, 32,
38], 87 quinazolin-4-one derivatives were identified with> 20% inhibition of S. aureus biofilm
at 100 or 50 μM [38]. Using the crystal violet (CV) staining microtiter-based biofilm assays, a
large number of compounds were screened to identify potential anti-biofilm reagents. There
have been many studies utilizing different assays to identify anti-biofilm agents [23]. Other
commonly used biofilm assays include using Resazurin (REZ) and benzene sulfonic acid
hydrate (XTT) assays that are based on the metabolic activity of the bacteria [23]. While there
could be a discrepancy between the results of the different biofilm assays, CV staining
Table 5. Drug release parameters for various cream formulations with CCG-211790.
Drug loading Release Rate (μg/cm2/
p
h) Cumulative Release Rate (%) Cumulative Release (μg) Final Concentration (μg/mL) R2
0.3% 107±21 38±7 251±35 16±2 0.9398
1.0% 233±18 27±4 559±55 36±4 0.9637
3.0% 562±53.0 39±3 1209±116 77±7 0.9899
https://doi.org/10.1371/journal.pone.0246408.t005
Fig 3. Drug release behavior (drug loading 0.3%, 1.0% and 3.0%).
https://doi.org/10.1371/journal.pone.0246408.g003
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screening is commonly used in many screening and testing studies for anti-biofilm reagents
[59–61], which quantifies the biomass of the biofilm and is easier to standardize due to its sim-
plicity and lower cost. Previous studies shown that the result of the CV staining of biofilm assay
correlated well with slime analysis and quantification of bacteria genomic DNA [62]. Kong et al.
have used an in vivo Caenorhabditis elegans (C. elegans)–S. aureus anti-infective screen to screen
a collection of 35 benzimidazole derivatives to identify compounds with anti-biofilm activity
with IC50 in the low μM range [61], in the similar range of IC50 as the anti-biofilm compound
in this study. The in vivo C. elegans–S. aureus anti-infective screen identified compounds that
can protect the nematodes from a lethal S. aureus infection. Since benzimidazole-derived
Table 6. Quality target product profile.
QTPP Elements Target Justification
Dosage form Cream Match indication
Dosage design O/W emulsion cream with CCG-211790 dissolved and
dispersed in the cream base
Route of administration Topical
Dosage strength 0.3%, 1.0% or 3.0% w/w To be determined by animal test
Stability No less than 24-month expiration dating period Match the shelf life of similar products
Drug product
quality attributes
Appearance White smooth cream with dissolved and dispersed CCG-
211790
Patient acceptability
pH 5.0~5.4 No irritation
Viscosity 12000 ~14000 cP Needed for applicability and drug release control
Identification Positive for CCG-211790 Needed for clinical effectiveness
Assay 90~110% of label claim
Content
Uniformity
Top, middle and bottom of three containers. Nice assay
values should be within 90.0%~110.0% label claim and
RSD� 5%.
Needed for clinical effectiveness
Impurities Any individual unknown: NMT 0.2%; total impurities:
NMT 0.5%
Needed for safety
Release behavior Release rate within 10~30% in 6 h To describe performance characteristics as a part of quality




Methyl paraben: 80.0~110.0% label claim; Needed for ensuring antimicrobial effectiveness
Microbial limits Meet USP <61> Needed for safety
Residual
solvents
Meet UPS <467> Needed for safety
Container closure system Container closure system qualified as suitable for this drug
product
Needed to achieve the target shelf-life and to ensure stability
during shipping and storage
Package integrity No failure Needed for stability, clinical effectiveness and safety
https://doi.org/10.1371/journal.pone.0246408.t006
Table 7. Stability of cream formulation.
Time Viscosity/cP pH
Day 1 13483±104 5.14
Temperature 25˚C 40˚C 25˚C 40˚C
Day 14 17200±312 15167±1841 5.14 5.19
Month 1 13783±896 16600±656 5.33 5.06
Month 3 13170±442 18683±925 5.24 5.32
Month 6 12383±275 10667±493 5.35 5.19
Month 9 11817±448 8590±592 5.33 5.18
Deceased by 12% 36%
https://doi.org/10.1371/journal.pone.0246408.t007
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molecules previously demonstrated anti-biofilm activity, CV staining assays were performed to
identify benzimidazole compounds with anti-biofilm activity against S. aureus. The benzimid-
azole compound was able to disrupt biofilm formation. The bacteria appeared as a monolayer
of dispersed cells scattered on the surface [61]. There are currently many efforts to develop anti-
biofilm agents, which contain moieties such as imidazole, phenols, indole, triazole, sulfide, fura-
none, bromopyrrole, peptides that are capable of disrupt and disperse biofilm [63]. Many of the
compounds are developed from scaffolds of naturally derived compounds [63]. Many of the
compounds have reported IC50 in middle to high μM range, with some of compounds have
reported IC50 in the low μM range [63], like in the current study.
The new compound CCG-211790 has better potency and a longer half-life when incubated
with mouse liver microsomes than the previously published compounds CCG-203592 and
CCG-205363 [17, 32]. This class of anti-biofilm compounds could inhibit the gene expression
of a number of S. aureus virulence factors involved in biofilm formation [17]. The compound
could disrupt the biofilm structure with less dense bacterial cell clusters in comparison with
the well-formed biofilm structures treated with control vehicle [17]. It is interesting that in
Kong et al’s. study, the benzimidazole compounds also disrupted the biofilm structure simi-
larly. The benzimidazole derivatives also inhibited the expression of a number of virulence fac-
tors such as the clumping factors (Clf) and serine-aspartate repeat-containing proteins (Sdr)
that promote adherence of bacteria to a substratum and induce staphylococcal biofilm forma-
tion [61]. Yet the gene expression profile affected by the quinazolin-4-one derivatives is differ-
ent from the benzimidazole compounds. For example, it was observed that the quinazolin-
4-one derivative markedly reduced expression of genes spa, LrgA and psmα [17], which wer-
en’t affected by benzimidazole compound, suggesting the two classes of compounds could tar-
get different sets of virulence factor expression. Nevertheless, it suggests that there are multiple
pathways that can be targeted to achieve anti-biofilm and anti-virulence activity.
It is thus concluded that this class of anti-biofilm compounds could disrupt biofilm forma-
tion and affect virulence gene expression in S. aureus [17]. On the other hand, the compounds
will need to be tested for their in vivo efficacy at mitigating infection in animal models which is
planned for future studies. CCG-211790 and its analogs represent a new class of anti-virulence
compounds which can inhibit S. aureus virulence and biofilm formation and has the potential
for treating biofilm-related diseases.
CCG-211790 is a novel anti-virulence compound with poor aqueous solubility (0.038
±0.01 μg/mL) and can be regarded as an insoluble compound in water. CCG-211790 solubility
in selected edible oils ranges from 20–37.2 mg/mL, giving potential for these edible oils to be
used as vehicles for CCG-211790 in formulation development. DMSO has relatively high sol-
vent power for CCG-211790 (66.7 mg/mL) and can be considered as a promising organic sol-
vent for CCG-211790 in preliminary studies. CCG-211790 retains chemical stability at most
physiological pH-values. Since poor aqueous solubility of drugs is usually associated with phar-
maceutical problems, effort was thus made for the development of CCG-211790 formulations
in order to enhance its pharmaceutical performance.
One important therapeutic application of this class of anti-biofilm compounds is to develop
a topical formulation to treat SSTIs. The skin covers the whole body and is the largest organ in
humans that could be subjected to various disorders and diseases. Topical products, which can
be administered easily and are portable, are widely used in treating a variety of diseases. Semi-
solid topical preparations are most commonly used. By incorporating drugs into semisolids,
they can exert their activity on the surface layers of tissues or with additional enhancers, pene-
trate into deeper layers at the site of action [64].
To explore the potential application of the novel anti-virulence compounds in treating
SSTIs, a topical cream of CCG-211790 was then developed and evaluated to access the bacteria
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in a wound. The emulsion was developed to possess the acceptable properties for drug release,
viscosity, pH, cosmetic elegance (odorless, non-greasy, spreadable, quick drying, and non-irri-
tating) and stability with over nine months testing. This study thus demonstrated that topical
formulation of this novel class anti-biofilm compounds can overcome the shortcomings of
CCG-211790’s poor water solubility to enable it to be released to the infection sites (~33-
156-fold of IC50) to exert its anti-biofilm activity against antibiotic resistant bacteria in the
wound which is on the surface of the skin (Fig 4).
The compound has some cytotoxicity at high concentration (50 μM). Stratum corneum will
greatly diminish the damage to the host skin cells by any potential cytotoxicity effect of the
compound. Further studies will be needed to assess the toxicity and tolerability of this topical
formulation along with efficacy studies in skin infection models.
Topical drug delivery could provide high local concentration of anti-virulence agents and
be used to validate the mechanism of action in animal studies and clinical trials to demonstrate
the potential of novel anti-virulence agents.
Conclusion
In summary, a novel anti-virulence compound was developed that could potentially be used to
treat or prevent SSTIs caused by MRSA. The mechanism of action will be to prevent or reduce
biofilm formation by antibiotic resistant pathogens and therefore help reduce or eliminate bac-
terial skin infections. The anti-virulence compound is different from conventional antibiotics
by not directly killing bacteria or blocking their proliferation, inducing less selective pressure
for drug resistance. The mechanism of action is “disarming” bacteria by lowering their ability
to form biofilm and harm the host. Blocking virulence factors that allow bacterial adaptation
to environmental changes will make bacteria more vulnerable to host defense and immunity
[8, 65]. A topical formulation with the acceptable properties for drug release, viscosity, pH,
cosmetic elegance and stability has been developed to overcome the poor water solubility of
the compound to enhance its therapeutic potential for treatment of SSTIs, in which antibiotic
resistance and biofilm formation are major challenge for conventional treatments.
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S1 Table. Original results of the effect of CCG-211790 on the biofilm formation of
NRS384.
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Fig 4. Topic formulation with CCG-211790 to treat wound infections via disarming the virulence factors of
bacteria. Bacteria form biofilm in the wound, which is recalcitrant to host defense and antibiotics. Topical cream
releases CCG-211790 to the site of infection to inhibit virulence factor expression and biofilm formation, to facilitate
host defense to fight infections.
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